XII AAEP News February 2022
INDUSTRY
Brief Summary of Prescribing Information. AAEP Educational Partner Profile: Zoetis
Zoetis has been committed to providing horse care you can count on for nearly 70 years. Our team includes numerous equine veterinarians and other experts who are inspired daily by the opportunity and profound responsibility to support horses, the owners who love them, and the equine veterinarians and other care team members who safeguard their wellbeing every day.
As the world’s leading animal health company, Zoetis is driven by a purpose to nurture our world and humankind by advancing care for animals.
Zoetis’ trailblazing approach to horse care drives our ongoing commitment to innovation. In 2018, Zoetis launched CORE EQ INNOVATOR®
, the first and only vaccine to contain all core equine
disease antigens to protect horses against West Nile virus, Eastern and Western equine encephalomyelitis, tetanus, and rabies—in one injection. In addition, Zoetis recently added Platinum Performance® products, the Stablelab®
nutrition point-of-care diagnostic blood test, and the Owl
Manor portfolio of regenerative medicine devices featuring Pro-Stride® APS to its portfolio, giving veterinarians even more ways to provide comprehensive care to equine patients.
Advancing the Equine Veterinary Profession As a longtime Educational Partner of the AAEP, Zoetis sponsors The Foundation for the Horse Scholarship for students and matches donations to the AAEP Equine Memorial Giving program. Additionally, Zoetis is proud to sponsor the AAEVT. The company’s support of the AAEP and AAEVT is part of the Zoetis Commitment to Veterinarians program that supports professionals in the industry through continuing education, veterinary wellness, research and development, and philanthropy.
In addition to supporting healthy horses and healthy veterinary practices, Zoetis is deeply committed to the health of the equine industry. Zoetis hosts local meetings and events at veterinary practices, as well as supports veterinarian/veterinary technical organizations including the NEAEP, FAEP, TEVA, NOMV and more. Zoetis also supports local and national horse competitions/events and our broader equine community, such as the American Horse Council, The Foundation for the Horse, American Quarter Horse Association’s Equine Research Foundation, The Right Horse Initiative and more.
For more information, visit
www.ZoetisEquine.com
(detomidine hydrochloride) Sedative and Analgesic For Use in Horses Only
Sterile Solution 10 mg/mL
CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
INDICATIONS: Dormosedan® is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfully for the following: to calm fractious horses, to provide relief from abdominal pain, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of skin lacerations, and castrations. Additionally, an approved, local infiltration anesthetic is indicated for castration.
CONTRAINDICATIONS: Dormosedan® should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or chronic renal failure. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal dysrhythmias may occur.
Information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports; therefore, this drug is not recommended for use in breeding animals.
WARNINGS: Do not use in horses intended for human consumption. Not for human use. Keep out of reach of children.
HUMAN SAFETY INFORMATION: Care should be taken to assure that detomidine hydrochloride is not inadvertently ingested as safety studies have indicated that the drug is well absorbed when administered orally. Standard ocular irritation tests in rabbits using the proposed market formulation have shown detomidine hydrochloride to be nonirritating to eyes. Primary dermal irritation tests in guinea pigs using up to 5 times the proposed market concentration of detomidine hydrochloride on intact and abraded skin have demonstrated that the drug is nonirritating to skin and is apparently poorly absorbed dermally. However, in accordance with prudent clinical procedures, exposure of eyes or skin should be avoided and affected areas should be washed immediately if exposure does occur. As with all injectable drugs causing profound physiological effects, routine precautions should be employed by practitioners when handling and using loaded syringes to prevent accidental self-injection.
PRECAUTIONS: Before administration, careful consideration should be given to administering Dormosedan® to horses approaching or in endotoxic or traumatic shock, to horses with advanced liver or kidney disease, or to horses under stress from extreme heat, cold, fatigue, or high altitude. Protect treated horses from temperature extremes. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers. Allowing the horse to stand quietly for 5 minutes before administration and for 10–15 minutes after injection may improve the response to Dormosedan®.
its use with other sedative or analgesic drugs for they may produce additive effects. Dormosedan® is a potent α2
When using any analgesic to help alleviate abdominal pain, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the pain.
Food and water should be withheld until the sedative effect of Dormosedan® has worn off.
-agonists, the potential for isolated cases of hypersensitivity exist, including paradoxical response (excitation).
-agonists. Reports of mild adverse reactions have resolved uneventfully without treatment. Severe adverse reactions should be treated symptomatically. As with all α2
SIDE EFFECTS: Horses treated with Dormosedan® exhibit hypertension. Bradycardia routinely occurs 1 minute after injection. The relationship between hypertension and bradycardia is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced bradycardia. Piloerection, sweating, salivation, and slight muscle tremors are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and respiratory rates. Urination typically occurs during recovery at about 45–60 minutes posttreatment, depending on dosage. Incoordination or staggering is usually seen only during the first 3–5 minutes after injection, until animals have secured a firm footing.
Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, edema of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.
OVERDOSAGE: Detomidine hydrochloride is tolerated in horses at up to 200 mcg/kg of body weight (10 times the low dosage and 5 times the high dosage). In safety studies in horses, detomidine hydrochloride at 400 mcg/kg of body weight administered daily for 3 consecutive days produced microscopic foci of myocardial necrosis in 1 of 8 horses.
68th Annual AAEP Convention
San Antonio November 18 – 22, 2022
HOW SUPPLIED: Dormosedan® is supplied in 5- and 20-mL multidose vials. NADA #140-862, Approved by FDA Manufactured by:
Distributed by: Zoetis Inc.
Kalamazoo, MI 49007
Revised: January 2013 107224US-10A&P Made in Finland
ADVERSE REACTIONS: Occasional reports of anaphylactic-like reactions have been received, including 1 or more of the following: urticaria, skin plaques, dyspnea, edema of the upper airways, trembling, recumbency, and death. The use of epinephrine should be avoided since epinephrine may potentiate the effects of α2
-agonist, and extreme caution should be exercised in ®
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
